Johnson & Johnson’s Profit Rises 19%

Johnson & Johnson’s third-quarter profit jumped 19%, helped by demand for medical devices and the arthritis medication Remicade.

Net income at the world’s fourth-biggest drug maker rose to $1.8 billion, or 60 cents a share, from $1.5 billion, or 49 cents, in the year-earlier period. Sales at the New Brunswick, N.J.-based company climbed 13% to $9.1 billion.

Johnson & Johnson shares rose $1.73 cents to $59.56 on the NYSE.